Beta Blockers in Heart Failure: Issues in Management of Individual Patients

[1]  L. Baruch,et al.  Beta-blockers in heart failure: Is more better? , 2004, Current heart failure reports.

[2]  Eric J. Eichhorn,et al.  Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. , 2000, The American journal of cardiology.

[3]  H. Krumholz.  β-blockers for mild to moderate heart failure , 1999, The Lancet.

[4]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[5]  H. Krumholz.  Beta-blockers for mild to moderate heart failure. , 1999, Lancet.

[6]  H. Krum,et al.  Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy , 1998 .

[7]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[8]  M. Packer,et al.  Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. , 1998, Circulation.

[9]  W. Abraham,et al.  Carvedilol improves renal hemodynamics in patients with chronic heart failure , 1998 .

[10]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[11]  M. Packer.  Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. , 1998, Progress in cardiovascular diseases.

[12]  J. Sackner-Bernstein.  Use of carvedilol in chronic heart failure: challenges in therapeutic management. , 1998, Progress in cardiovascular diseases.

[13]  T. Yue,et al.  Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. , 1998, Progress in cardiovascular diseases.

[14]  W. Abraham,et al.  Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.

[15]  T. Yue,et al.  Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. , 1998, Circulation research.

[16]  J. Port,et al.  Echocardiographic and Histopathological Characterization of Young and Old Transgenic Mice Over-expressing the Human β1-Adrenergic Receptor , 1998 .

[17]  M. Metra,et al.  Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure. , 1998, European heart journal.

[18]  J. Cleland,et al.  Beta-blockers for chronic heart failure: from prejudice to enlightenment. , 1998, Journal of cardiovascular pharmacology.

[19]  G. Sinagra,et al.  Effects of carvedilol on LV function and remodeling in patients with dilated cardiomyopathy with persistent LV dysfunction despite optimal conventional therapy , 1998 .

[20]  B. Carabello,et al.  Beta blockade must be added to ACE inhibition to improve hemodynamics and contractile function in experimental mitral regurgitation , 1998 .

[21]  M. Bristow.  Mechanism of action of beta-blocking agents in heart failure. , 1997, The American journal of cardiology.

[22]  M. Packer.  Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. , 1997, The American journal of cardiology.

[23]  D. Blumenthal,et al.  National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. , 1997, Archives of internal medicine.

[24]  F. Waagstein.  Efficacy of beta blockers in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. , 1997, The American journal of cardiology.

[25]  R. Cody,et al.  The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. , 1997, American Journal of Cardiology.

[26]  G. Fishman,et al.  Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. , 1997, The Journal of clinical investigation.

[27]  M. Hetzel,et al.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). , 1997, Circulation.

[28]  G. Billman,et al.  Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. , 1997, Circulation.

[29]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[30]  R. Senior,et al.  Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. , 1997, Circulation.

[31]  P. Heidenreich,et al.  Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. , 1997, Journal of the American College of Cardiology.

[32]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[33]  R. Doughty,et al.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .

[34]  M. Bristow,et al.  Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. , 1997, The American journal of cardiology.

[35]  M. Packer.  End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? , 1997, The New England journal of medicine.

[36]  BengtRundqvist,et al.  Increased Cardiac Adrenergic Drive Precedes Generalized Sympathetic Activation in Human Heart Failure , 1997 .

[37]  M. Metra,et al.  Comparative effects of metoprolol and carvedilol on resting and peak exercise hemodynamics and functional capacity in patients with chronic heart failure. , 1997 .

[38]  S. Vatner,et al.  Cardiomyopathy induced by cardiac Gs alpha overexpression. , 1997, The American journal of physiology.

[39]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[40]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[41]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[42]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[43]  K. Swedberg,et al.  Beta-blocking agents in heart failure. Should they be used and how? , 1996, European heart journal.

[44]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[45]  C R Benedict,et al.  Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. , 1996, Circulation.

[46]  G. Newton,et al.  Acute Effects of β1-Selective and Nonselective β-Adrenergic Receptor Blockade on Cardiac Sympathetic Activity in Congestive Heart Failure , 1996 .

[47]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[48]  J. Port,et al.  Cardiac adrenergic receptor effects of carvedilol. , 1996, European heart journal.

[49]  G. Newton,et al.  Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. , 1996, Circulation.

[50]  S. Vatner,et al.  Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. , 1996, Circulation research.

[51]  E. J. Benjamin,et al.  Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. , 1995, Journal of the American College of Cardiology.

[52]  G. Jennings,et al.  Adverse consequences of high sympathetic nervous activity in the failing human heart. , 1995, Journal of the American College of Cardiology.

[53]  H. Krum,et al.  Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. , 1995, Circulation.

[54]  S. Viskin,et al.  Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. , 1995, Journal of the American College of Cardiology.

[55]  D. Renlund,et al.  Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.

[56]  P. Grayburn,et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.

[57]  Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. , 1995, Circulation.

[58]  E J Eichhorn,et al.  Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. , 1995, Journal of the American College of Cardiology.

[59]  M. Metra,et al.  Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[60]  J. Cohn,et al.  Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. , 1994, Journal of the American College of Cardiology.

[61]  P. Grayburn,et al.  Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.

[62]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[63]  M. Metra,et al.  Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. , 1994, American heart journal.

[64]  W. French,et al.  Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.

[65]  R. Doughty,et al.  Beta-blockers in heart failure: promising or proved? , 1994, Journal of the American College of Cardiology.

[66]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[67]  R. Nadeau,et al.  Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in dogs. , 1993, The American journal of physiology.

[68]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[69]  M. Packer.  How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. , 1993, The American journal of cardiology.

[70]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[71]  E. Sonnenblick,et al.  Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. , 1992, European heart journal.

[72]  M. Rosen,et al.  An alpha-1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. , 1991, Circulation.

[73]  K. Baker,et al.  Cardiac Hypertrophy: Mechanical, Neural, and Endocrine Dependence , 1991 .

[74]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[75]  P. Binkley,et al.  Alpha-adrenergic component of the sympathetic nervous system in congestive heart failure. , 1990, Circulation.

[76]  M. Brown,et al.  Selective j31-Adrenoceptor Blockade Enhances Positive Inotropic Responses toEndogenous Catecholamines Mediated Through j2-Adrenoceptors inHumanAtrial Myocardium , 1990 .

[77]  K Caidahl,et al.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.

[78]  M. Michel,et al.  Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. , 1989, Journal of the American College of Cardiology.

[79]  J. Port,et al.  Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. , 1989, Molecular pharmacology.

[80]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[81]  J. Reid,et al.  Epinephrine-induced hypokalemia: the role of beta adrenoceptors. , 1986, The American journal of cardiology.

[82]  S. Umemura,et al.  Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin. , 1985, Circulation research.

[83]  M. Bristow,et al.  Rationale for beta-adrenergic blocking drugs in cardiomyopathy. , 1985, The American journal of cardiology.

[84]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[85]  E. Johns,et al.  The role of α‐adrenoceptors in the regulation of renal tubular sodium reabsorption and renin secretion in the rabbit , 1985, British journal of pharmacology.

[86]  K. Swedberg,et al.  Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. , 1985, The American journal of medicine.

[87]  M. Bristow.  The adrenergic nervous system in heart failure. , 1984, The New England journal of medicine.

[88]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[89]  P. Simpson.  Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. , 1983, The Journal of clinical investigation.

[90]  J. Kjekshus,et al.  Timolol‐related Reduction in Mortality and Reinfarction in Patients Ages 65‐75 Years Surviving Acute Myocardial Infarction , 1982, Circulation.

[91]  J. Cohn,et al.  Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. , 1982, American heart journal.

[92]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[93]  S. Stephen.  Unwanted effects of propranolol. , 1966, The American journal of cardiology.

[94]  E. Braunwald,et al.  The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.

[95]  Jeffrey L. Anderson,et al.  Dose-Response of Chronic / 3-Blocker Treatment in Heart Failure From Either Idiopathic Dilated or Ischemic Cardiomyopathy , 2005 .